NCT02750332View on ClinicalTrials.gov

Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions

Hereditary Tyrosinemia, Type I

Interventions

DRUG

Nitisinone

A single oral dose of Nitisinone 10 mg Tablet will be administered.

Trial Locations (1)

9301

Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein

Sponsors

Lead Sponsor

Cycle Pharmaceuticals Ltd.

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

Cycle Pharmaceuticals Ltd.

INDUSTRY